Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.07.002 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Lina Elsayed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Paclitaxel, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The evolution of systemic therapies has improved outcomes for patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer. Nonetheless, the tolerability and safety profile of systemic therapies represent an area for further improvement. Here we report the results of a phase 2 trial evaluating a nonanthracycline, nonplatinum adjuvant treatment regimen for patients following initial surgical resection. METHODS: We enrolled patients with stage I or II HER2+ breast cancer who underwent upfront surgery to receive adjuvant treatment with 6 cycles of dose-dense Paclitaxel, cyclophosphamide and Trastuzumab (PC-H) every 2 weeks, followed by 13 cycles of maintenance trastuzumab every 3 weeks to complete 52 weeks of treatment (compromising 19 cycles). The primary objective was to determine the safety and feasibility of adjuvant PC-H, measured by the completion rate frequency and the grade of adverse events, using National Cancer Institute Common Terminology Criteria. The secondary objective was to estimate relapse-free survival and overall survival. RESULTS: Between 2010 and 2019, a total of 39 patients were enrolled. Of those, 34 patients (87.18%) completed the planned treatment. Severe adverse events of grade 3 or 4 occurred in 27 patients (69.23%), including 3 patients (7.69%) with grade 3-4 decrease in ejection fraction. At median follow up of 5.6 years, all 39 patients were alive. The 5-year relapse-free survival was 94.30% (95% CI: 75.3-100). CONCLUSIONS: PC-H demonstrated overall safety and efficacy, yielding high rates of relapse-free survival among patients with early stage (HER2+) breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE.
- Mary Lanning Healthcare, Morrison Cancer Center, Department of Medicine, University of Nebraska Medical Center, Omaha, NE.
- Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE.
- Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE. Electronic address: jairam.krishnamurthy@unmc.edu.
Zitieren
APA
Elsayed, L., Reed, E., Modi, S., Tandra, P. K., Copur, M. S., Samson, K., & Krishnamurthy, J. (2024). Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.07.002
Vancouver
Elsayed L, Reed E, Modi S, Tandra PK, Copur MS, Samson K, et al. Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.07.002
BibTeX
@article{Elsayed2024,
author = {Elsayed, Lina and Reed, Elizabeth and Modi, Shivani and Tandra, Pavan K and Copur, Mehmet S and Samson, Kaeli and Krishnamurthy, Jairam},
title = {Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.07.002}
}
EUVIMED